Document is current
Any future updates will be listed below
-
Authors
Volpedo, Greta https://orcid.org/0000-0002-1112-7715
Pacheco-Fernandez, Thalia https://orcid.org/0000-0003-2741-0942
Holcomb, Erin A. https://orcid.org/0000-0003-1368-9858
Zhang, Wen-Wei
Lypaczewski, Patrick https://orcid.org/0000-0002-5550-712X
Cox, Blake
Fultz, Rebecca
Mishan, Chelsea
Verma, Chaitenya
Huston, Ryan H. https://orcid.org/0000-0003-1884-1695
Wharton, Abigail R.
Dey, Ranadhir
Karmakar, Subir
Oghumu, Steve
Hamano, Shinjiro https://orcid.org/0000-0003-3881-8337
Gannavaram, Sreenivas https://orcid.org/0000-0002-6557-8220
Nakhasi, Hira L.
Matlashewski, Greg
Satoskar, Abhay R. https://orcid.org/0000-0001-5989-1520
-
Funding
Funding for this research was provided by:
Global Health Innovative Technology (GHIT) Fund
- License Information
-
More Information
Article History
Received: 13 August 2021
Accepted: 27 January 2022
First Online: 2 March 2022
Competing interests
: The FDA is currently a co-owner of two US patents that claim attenuated <i>Leishmania</i> species with the <i>centrin</i> gene deletion (US7,887,812 and US 8,877,213). This article reflects the views of the authors and should not be construed to represent FDA’s views or policies. The remaining authors declare no competing interests.
